Bettina Hamelin's lobbying: the registrations they file and every meeting they've reported since November 2021.
← LobbyingRegistrant (responsible officer)
President and CEO
For companies and organizations, the most senior paid officer files the registration and the monthly reports, whoever attended the meeting.
Former public office
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry
Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Proposed pharmacare legislation related to any future national pharmacare program
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry
Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework
Proposed pharmacare legislation related to any future national pharmacare program
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
Proposed pharmacare legislation related to any future national pharmacare program
Free trade agreements as they relate to the biopharmaceutical industry
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry
Proposed pharmacare legislation related to any future national pharmacare program
Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework
Free trade agreements as they relate to the biopharmaceutical industry
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
Free trade agreements as they relate to the biopharmaceutical industry
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Free trade agreements as they relate to the biopharmaceutical industry
Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Free trade agreements as they relate to the biopharmaceutical industry
Proposed pharmacare legislation related to any future national pharmacare program
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
Free trade agreements as they relate to the biopharmaceutical industry
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry
Free trade agreements as they relate to the biopharmaceutical industry
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.